Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery

✍ Scribed by Chen, Michael Y.M.; Chiles, Caroline; Loggie, Brian W.; Choplin, Robert H.; Perini, Mark A.; Fleming, Ronald A.

• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: English
• Weight: 95 KB
• Volume: 66
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/(sici)1096-9098(199709)66:1<19::aid-jso5>3.0.co;2-q

✦ Synopsis

Background:

The purpose of this study was to determine the incidence and severity of thoracic reactions in patients undergoing intraperitoneal heated chemotherapy (IPHC). Methods: Forty-two patients who had intraperitoneal disseminated malignancies were treated with cytoreductive surgery (CS) and IPHC. The primary malignancies included carcinoma of the colon (n ‫ס‬ 17), stomach (n ‫ס‬ 6), appendix (n ‫ס‬ 6), pseudomyxoma peritonei (n ‫ס‬ 3), mesothelium (n ‫ס‬ 2), ovaries (n ‫ס‬ 2), jejunum (n ‫ס‬ 2), gallbladder (n ‫ס‬ 1), urachus (n ‫ס‬ 1), and peritoneal carcinomatosis (n ‫ס‬ 2). After CS, IPHC with mitomycin (MMC) was administered by perfusion at 40.5°C. After IPHC, multiple radiographs of the chest were reviewed in comparison to the control group. Results: Thoracic complications occurred in 36 patients (86%), including atelectasis in 32 patients (76%), pleural effusions in 27 (64%), pulmonary edema in 10 (24%), pneumonia in 2 (5%), and pneumothorax in 2 (5%). The incidence of thoracic complications in the IPHC group was significantly higher than that of patients in the control group (P < .05). Correlations between the prevalence of pleural effusion and the dose of MMC, duration of procedure, and presence of thrombocytopenia were not significant (P > .05). Conclusions: Bibasilar atelectasis and pleural effusions are common findings after IPHC with MMC, but most of them do not necessarily warrant intervention.